Besides, m6A modifications frequently involve key components of oncogenic signaling pathways, including WNT/β-catenin, phosphatidylinositol-3-kinase (PI3K)/Akt and mammalian target of rapamycin (mTOR) signaling pathways [4], thereby contributing to their aberrant activation in cancer. Here, MTOR is linked to cancer.